A PYMNTS Company

US: Novartis win antitrust appeal

By  |  August 22, 2018

According to a report from Reuters, a federal appeals court on Tuesday, August 21, upheld the dismissal of two proposed class actions alleging that Novartis engaged in a monopolistic scheme to delay the introduction of generic versions of its leukemia drug Gleevec into the US market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The 1st US Circuit Court of Appeals in Boston ruled that direct purchasers of Gleevec, as well as health plans which indirectly bought the drug, had failed to sufficiently allege Novartis’ actions violated antitrust law.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.